7-o-(2,6-dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, CK; Kim, WB; Lee, ED; Lee, JJ; Lee, MG; Lee, SD; Lee, WI; Park, JB; Shim, HJ; Yang, J | 1 |
| Im, YH; Kang, YK; Kim, BS; Kim, TY; Lee, CT; Park, YH; Ryoo, BY | 1 |
1 trial(s) available for 7-o-(2,6-dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride and Lung Neoplasms
| Article | Year |
|---|---|
A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1999 |
1 other study(ies) available for 7-o-(2,6-dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride and Lung Neoplasms
| Article | Year |
|---|---|
Pharmacokinetics and antitumour activity of a new anthracycline, DA-125, after intravenous administration to subcutaneously implanted Lewis-lung-carcinoma-bearing mice.
Topics: Animals; Anti-Infective Agents; Biotransformation; Carcinoma; Chromatography, High Pressure Liquid; Doxorubicin; Female; Half-Life; Injections, Intravenous; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Tissue Distribution | 1995 |